MapLight Therapeutics (MPLT) Current Assets (2024 - 2026)

MapLight Therapeutics (MPLT) posted Current Assets of $324.7 million for Q4 2025, up 32.35% sequentially from $245.3 million in Q3 2025, and up 183.3% YoY from $114.6 million in Q4 2024.

MapLight Therapeutics (MPLT) Current Assets (2024 - 2026) Analysis & Trends

MapLight Therapeutics has reported Current Assets for 2 years, with the latest figure at $324.7 million in Q4 2025.

  • Quarterly Current Assets rose 183.3% year-over-year to $324.7 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $324.7 million (up 183.3% YoY) and the FY2025 annual result came in at $324.7 million, up 183.3% from the prior year.
  • Current Assets grew to $324.7 million in Q4 2025 per MPLT's latest filing, from $245.3 million in the prior quarter.
  • Over five years, Current Assets peaked at $324.7 million in Q4 2025 and troughed at $114.6 million in Q4 2024.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Current Assets (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn 12.54 Bn
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn 18.45 Bn
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn 8.07 Bn
4 Revolution Medicines 43.64 Bn 43.64 Bn - 4.03 Bn
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 7.22 Bn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 11.83 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 1.76 Bn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn 4.62 Bn
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn 1.63 Bn
10 MapLight Therapeutics 533.88 Mn 533.88 Mn - 318.79 Mn

Historic Data

Download Data
DateValue
Jun 30, 2026 318.79 Mn
Dec 31, 2025 324.67 Mn
Sep 30, 2025 245.31 Mn
Dec 31, 2024 114.60 Mn